Axpaxli edges Eylea on vision retention with fewer injections, but durability gap narrows

Ocular Therapeutix reported that Axpaxli met a key endpoint in a Phase 3 wet AMD trial by maintaining patients’ vision with fewer injections than the standard treatment. At 9 and 12 months after a single injection, 74% and 66% of Axpaxli patients maintained vision versus 56% and 44% for low-dose Eylea. While the primary goal was achieved, the durability advantage over Eylea was smaller than investors expected, which could influence the drug’s commercial potential as the company pursues FDA approval.